Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$90.01

5.26 (6.21%)

, AMGN

Amgen

$184.88

-0.72 (-0.39%)

10:48
09/28/17
09/28
10:48
09/28/17
10:48

AbbVie settlement should shift debate on shares, says Piper Jaffray

AbbVie (ABBV) and Amgen's (AMGN) global resolution of all intellectual property-related litigation relating to Humira should further reinforce the validity of AbbVie's intellectual property beyond its recent inter partes review victories, Piper Jaffray analyst Richard Purkiss tells investors in a research note. The analyst raised his price target for AbbVie shares to $102 from $102 saying the settlement likely extends by five months his most recent assumption on the timing of U.S. biosimilar entry. Further, greater certainty on Humira biosimilar should shift the debate on AbbVie shares to the pipeline, Purkiss contends. He reiterates an Overweight rating on the name.

ABBV

AbbVie

$90.01

5.26 (6.21%)

AMGN

Amgen

$184.88

-0.72 (-0.39%)

  • 08

    Nov

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

ABBV AbbVie
$90.01

5.26 (6.21%)

09/28/17
JEFF
09/28/17
NO CHANGE
Target $107
JEFF
Buy
AbbVie Humira settlement increases visibility, says Jefferies
Jefferies analyst Jeffrey Holford said AbbVie's (ABBV) settlement of its patent fight with Amgen (AMGN) over Humira provides incremental reassurance that biosimilars are unlikely to launch in the U.S. before 2023. While there will still be "noise" on this issue given the many biosimilar developers, he recommends investors focus on AbbVie's pipeline, whose value should become more visible within the next year. Holford keeps a Buy rating and $107 price target on AbbVie shares.
09/27/17
FBCO
09/27/17
NO CHANGE
Target $17
FBCO
Outperform
Coherus Biosciences price target lowered to $17 from $24 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Coherus Biosciences (CHRS) to $17 from $24 as she is pushing her worldwide launch timeline assumption to 2022 from 2020 for the biosimilar Humira from AbbVie (ABBV). The analyst reiterates an Outperform rating on Coherus Biosciences shares.
09/25/17
09/25/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UAA) downgraded to Neutral from Buy at Guggenheim. 2. VF Corp. (VFC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Edward Yruma saying the company's "consistent" results are adequately reflected in the current valuation. 3. Quest Diagnostics (DGX) downgraded to Market Perform from Outperform at Raymond James with analyst Nicholas Jansen citing the preliminary 2018 Clinical Laboratory Fee Schedule, or CLFS, rates released Friday evening, which creates an overhang. 4. AbbVie (ABBV) downgraded to Neutral from Buy at UBS with analyst Marc Goodman saying that shares are up 40% year-to-date. 5. Albemarle (ALB) downgraded to Neutral from Outperform at Baird with analyst Ben Kallo saying he thinks near-term execution is largely priced into the stock and he believes the shares are fully valued at current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/25/17
JEFF
09/25/17
NO CHANGE
Target $200
JEFF
Buy
Jefferies explains how Amgen can re-rate higher like AbbVie
Jefferies analyst Michael Yee believes the 2018-2020 consensus estimates for Amgen (AMGN) may be too low if Mylan's (MYL) biosimilar of Neulasta doesn't get approved next month. The Biosimilar User Fee Act date is October 9. Investors may become more confident in the durability of Amgen's franchise given that AbbVie (ABBV) defended Humira and re-rated to a higher valuation, Yee tells investors in a research note. The key issue keeping Amgen's price-to-earnings multiple below peers at 12 to 13 times over the past couple of years is investor fear of biosimilars primarily against Neulasta and Enbrel, Yee argues. He sees a failed approval for Mylan as setting the tone for a higher multiple like AbbVie. The analyst has a Buy rating on Amgen shares with a $200 price target.
AMGN Amgen
$184.88

-0.72 (-0.39%)

09/21/17
UBSW
09/21/17
NO CHANGE
Target $500
UBSW
Buy
Regeneron price target lowered to $500 from $535 at UBS
UBS analyst Carter Gould lowered his price target on Regeneron (REGN) to $500 from $535 citing increased Dupixent competition after Amgen (AMGN) and AstraZeneca (AZN) reported data on their own asthma drug earlier this month and AbbVie (ABBV) reported results in an atopic dermatitis study. While he noted that definitive 12-month phase 3 data from these competitors is likely more than 20 months away, he also lowered his Dupixent peak sales estimate to $4.8B from $6.5B. He keeps a Buy rating on Regeneron shares, as he believes pipeline products including nesvacumab and REGN2810 offer a path to longer-term upside.
09/14/17
RBCM
09/14/17
INITIATION
Target $192
RBCM
Sector Perform
Amgen initiated with a Sector Perform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Amgen with a Sector Perform and an $192 price target.

TODAY'S FREE FLY STORIES

UNP

Union Pacific

$111.94

1.56 (1.41%)

15:50
10/19/17
10/19
15:50
10/19/17
15:50
Options
Union Pacific calls see another day of extraordinary volume »

Union Pacific calls see…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SRC

Spirit Realty

$8.08

-0.39 (-4.60%)

15:49
10/19/17
10/19
15:49
10/19/17
15:49
Hot Stocks
Spirit Realty weakness attributed to report of Sun Capital seeking Shopko buyer »

The weakness in shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

FTR

Frontier Communications

15:45
10/19/17
10/19
15:45
10/19/17
15:45
Options
Frontier Communications call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

CZFC

Citizens First

15:42
10/19/17
10/19
15:42
10/19/17
15:42
Hot Stocks
Citizens First raises semiannual dividend 25% to 10c per share »

On October 19, the Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKX

Skechers

$24.15

-0.955 (-3.80%)

15:34
10/19/17
10/19
15:34
10/19/17
15:34
Options
Skechers options imply 14.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

BCS

Barclays

$10.16

0.01 (0.10%)

15:31
10/19/17
10/19
15:31
10/19/17
15:31
Periodicals
Barclays being sued for $850M for copper market abuse, Bloomberg reports »

Red Kite Management is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

GE

General Electric

$23.72

0.595 (2.57%)

15:30
10/19/17
10/19
15:30
10/19/17
15:30
Options
100K GE Oct 27th 21.5 puts trade ahead of earnings »

100K GE Oct 27th 21.5…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

GE

General Electric

$23.72

0.595 (2.57%)

15:29
10/19/17
10/19
15:29
10/19/17
15:29
Technical Analysis
Technical Earnings Preview: General Electric in well-defined downtrend »

Shares have been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

WFBI

WashingtonFirst

$36.23

-0.25 (-0.69%)

15:28
10/19/17
10/19
15:28
10/19/17
15:28
Earnings
WashingtonFirst reports Q3 core EPS 43c, consensus 41c »

WashingtonFirst President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$997.00

-12.13 (-1.20%)

15:25
10/19/17
10/19
15:25
10/19/17
15:25
Hot Stocks
Analysis of buyer shopping patterns shows Amazon Prime has 90M members »

Consumer Intelligence…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 26

    Oct

  • 18

    Mar

PLUG

Plug Power

$2.55

-0.12 (-4.49%)

15:23
10/19/17
10/19
15:23
10/19/17
15:23
Conference/Events
Plug Power to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

HON

Honeywell

$143.65

0.21 (0.15%)

15:21
10/19/17
10/19
15:21
10/19/17
15:21
Technical Analysis
Technical Earnings Preview: Honeywell in bullish channel ahead of earnings »

The stock has been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

ETFC

E-Trade

$43.92

0.14 (0.32%)

15:19
10/19/17
10/19
15:19
10/19/17
15:19
Options
E Trade options imply 4.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 21

    Oct

  • 07

    Nov

$NSD

NASDAQ Market Internals

15:17
10/19/17
10/19
15:17
10/19/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
10/19/17
10/19
15:16
10/19/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$159.76

-0.71 (-0.44%)

, HNHPF

Hon Hai Precision

$7.49

0.412 (5.82%)

15:12
10/19/17
10/19
15:12
10/19/17
15:12
Hot Stocks
Apple drags on Nasdaq after report of reduced iPhone 8 orders »

Shares of Apple (AAPL)…

AAPL

Apple

$159.76

-0.71 (-0.44%)

HNHPF

Hon Hai Precision

$7.49

0.412 (5.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

ISRG

Intuitive Surgical

$354.37

-0.63 (-0.18%)

15:04
10/19/17
10/19
15:04
10/19/17
15:04
Options
Intuitive Surgical options imply 5.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

BCS

Barclays

15:03
10/19/17
10/19
15:03
10/19/17
15:03
Periodicals
Breaking Periodicals news story on Barclays »

Red Kite sues Barclays…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

DB

Deutsche Bank

$16.88

-0.015 (-0.09%)

15:02
10/19/17
10/19
15:02
10/19/17
15:02
Hot Stocks
Apex Group, Genstar announce acquisition of Deutsche Bank AFS business »

Apex Group and Genstar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

PG

Procter & Gamble

$91.50

-0.5804 (-0.63%)

15:01
10/19/17
10/19
15:01
10/19/17
15:01
Technical Analysis
Technical Earnings Preview: Procter & Gamble in uptrend before news »

The stock has been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

14:55
10/19/17
10/19
14:55
10/19/17
14:55
General news
Trump already met with Yellen today »

Trump already met with…

AMZN

Amazon.com

$997.00

-12.13 (-1.20%)

14:53
10/19/17
10/19
14:53
10/19/17
14:53
Periodicals
Small grocers team up with Amazon to increase sales, Handelsblatt Global says »

Small German grocery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 26

    Oct

  • 18

    Mar

AAPL

Apple

$159.76

-0.71 (-0.44%)

14:50
10/19/17
10/19
14:50
10/19/17
14:50
Options
Apple implied volatility reaches 52-week highs »

Apple implied volatility…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

PYPL

PayPal

$67.26

0.59 (0.88%)

14:49
10/19/17
10/19
14:49
10/19/17
14:49
Options
PayPal options imply 6.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 29

    Nov

NBR

Nabors Industries

$6.75

-0.325 (-4.60%)

14:45
10/19/17
10/19
14:45
10/19/17
14:45
Options
Nabors Industries call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 15

    May

  • 16

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.